# Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)

> **NCT05322850** · PHASE1,PHASE2 · SUSPENDED · sponsor: **University of Florida** · enrollment: 40 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Acute Lymphoid Leukemia
- Mixed Phenotype Acute Leukemia
- Acute Undifferentiated Leukemia
- Chronic Myeloid Leukemia in Myeloid Blast Crisis
- Chronic Myeloid Leukemia in Lymphoid Blast Crisis (Diagnosis)
- Chronic Myeloid Leukemia - Accelerated Phase

## Interventions

- **BIOLOGICAL:** Orca-Q

## Key facts

- **NCT ID:** NCT05322850
- **Lead sponsor:** University of Florida
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2022-08-16
- **Primary completion:** 2026-09
- **Final completion:** 2027-09
- **Target enrollment:** 40 (ESTIMATED)
- **Why stopped:** Seeking additional funding sources
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05322850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05322850, "Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05322850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*